Log In or Register to Join The Conversation!

PTC's RG7916 is Early, But on the Rise

This topic has 0 replies, 1 voice, and was last updated 2 years, 9 months ago by Anonymous.

  • Author
    • #11191

      It’s too soon to get super excited about PTC Therapeutics’ experimental therapy RG7916, but the early data is looking promising. In the company’s phase 1 clinical trial, “Preliminary findings of 13 babies enrolled — extending to week 35 of treatment in three of them . . . show that none have lost the ability to swallow or required ventilation in order to breathe, and eight of nine infants evaluated at week eight also were swallowing and breathing on their own.”

      Read the full story here.

      PTC is also developing therapies for DMD, and last year purchased Emflaza, a DMD therapeutic. While developing DMD therapies has proved to be elusive (not just for PTC, but for the entire industry), PTC’s early clinical work with RG7916 suggests that there is more coming down the pipeline than just AVXS-101.

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2020 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?


Create Account

Copyright © 2017-2020 All rights reserved.